Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis: results from the international ALL trial MRC UKALL XII/ECOG E2993
Authors:
- Hillard M. LazarusHLHillard M. Lazarus
- Susan M. RichardsSRSusan M. Richards
- Raj ChopraRCRaj Chopra
- Mark R. LitzowMLMark R. Litzow
- Alan K. BurnettABAlan K. Burnett
- Peter H. WiernikPWPeter H. Wiernik
- Ian M. FranklinIFIan M. Franklin
- Martin S. TallmanMTMartin S. Tallman
- Lucy CookLCLucy Cook
- Georgina BuckGBGeorgina Buck
- I. Jill DurrantIDI. Jill Durrant
- Jacob M. RoweJRJacob M. Rowe
- 15 July 2006
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 108 (2) , 465-472
Abstract
Outcome of acute lymphoblastic leukemia (ALL) in adults with central nervous system (CNS) disease at diagnosis is unclear. We treated 1508 de novo ALL patients with 2-phase induction and then high-dose methotrexate with l-asparaginase. Patients up to 50 years old in first remission (CR1) with a matched related donor (MRD) underwent an allogeneic stem cell transplantation (SCT); the remainder in CR1 were randomized to an autologous SCT or intensive consolidation followed by maintenance chemotherapy. Philadelphia chromosome (Ph)–positive patients were offered a matched unrelated donor (MUD) allogeneic SCT. Seventy-seven of 1508 (5%) patients a median age of 29 years had CNS leukemia at presentation; 13 of the 77 (17%) had Ph-positive ALL. Sixty-nine of 77 (90%) patients attained CR1. Thirty-six patients underwent transplantation in CR1 (25 MRD, 5 MUD, and 6 autografts). Eleven of 25 patients with MRD transplantation remain alive at 21 to 102 months, 2 of 5 with MUD at 42 and 71 months, and 1 of 6 with autologous SCT at 35 months. Seven of 27 treated with consolidation/maintenance remain in CR1 56 to 137 months after diagnosis. Overall survival at 5 years was 29% in those with CNS involvement at diagnosis versus 38% (P = .03) for those without. CNS leukemia in adult ALL is uncommon at diagnosis. Adult Ph-negative ALL patients, however, can attain long-term disease-free survival using SCT as well as conventional chemotherapy.Keywords
This publication has 23 references indexed in Scilit:
- Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993Blood, 2005
- Outcome Of CNS Disease At Diagnosis in Disseminated Small Noncleaved-Cell Lymphoma and B-Cell Leukemia: A Children’s Cancer Group StudyJournal of Clinical Oncology, 2000
- Results of Treatment With Hyper-CVAD, a Dose-Intensive Regimen, in Adult Acute Lymphocytic LeukemiaJournal of Clinical Oncology, 2000
- Hyper-CVAD Program in Burkitt's-Type Adult Acute Lymphoblastic LeukemiaJournal of Clinical Oncology, 1999
- Prospective karyotype analysis in adult acute lymphoblastic leukemia: the cancer and leukemia Group B experience.1999
- Treatment of adult acute lymphoblastic leukemia.1997
- Cytogenetic abnormalities in adult acute lymphoblastic leukemia: correlations with hematologic findings outcome. A Collaborative Study of the Group Français de Cytogénétique Hématologique.1996
- Improved outcome in adult B-cell acute lymphoblastic leukemiaBlood, 1996
- A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811Blood, 1995
- Acute lymphocytic leukaemia in the elderly: characteristics and outsome with the vincristine‐adriamycin‐dexamethasone (VAD) regimenBritish Journal of Haematology, 1994